Table 1 Overview of assessments and instruments
Assessments (researchers) | Baseline | Week 4• | Week 8• | Week 12 |
|---|---|---|---|---|
Checklist inclusion criteria (control and experimental) | • |  |  |  |
CIDI - Substance Abuse Module (cocaine& heroine& alcohol) | • |  |  |  |
MINI - Suicidal risk | • |  |  |  |
Addiction Severity Index + supplement1 | • |  |  |  |
Addiction Severity Index; short version substance use + supplement1 |  | • | • | • |
Time Line Follow-Back (cocaine) | • | • | • | • |
Maudsley Addiction Profile (MAP) - HSS | • | • | • | • |
Symptom Check List- 90 (SCL-90) | • | • | • | • |
Obsessive Compulsive Drug Use Scale (OCDUS) | • | • | • | • |
Client Satisfaction Questionnaire- 8 (CSQ-8) + supplement2 |  |  |  | • |
Evaluation (control and experimental) |  |  |  | • |
Medical assessment (physician) | Baseline | Week 4 • | Week 8 • | Week 12 |
Checklist exclusion criteria (control and experimental) | • |  |  |  |
First informed consent (control and experimental) | • |  |  |  |
Second informed consent (only experimental) | • |  |  |  |
Medical assessment: ECG (only dexamphetamine study) | • |  |  | • |
Medical assessment: blood analysis (week 12 only experimental) | • |  |  | • |
Medical screening: heart rate, blood pressure3 (only experimental) | • | • • • • | • • • • | • • • • |
Pregnancy (only experimental; only women) | • | • | • | • |
(Serious) adverse events (only experimental) | • | • • • • | • • • • | • • • • |
Drug accountability (only dexamphetamine study) |  | • • • • | • • • • | • • • • |
Urinalysis cocaine- metabolites (control and experimental; obtained by research assistant) | • |  |  | • • • • |
Treatment participation (consumption of care; medication) (control and experimental) |  | • • • • | • • • • | • • • • |